Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 Breakthroughs that change patients’ livesPfizer Oncology Analyst and Investor Session Andy Schmeltz Chris Boshoff Jeff Settleman April 9th, 2021
1 Breakthroughs that change patients’ livesPfizer Oncology
April 9th, 2021 2 Oncology•Our discussions during this presentation include forward- looking statements about our anticipated operating and financial
performance, business plans and prospects, expectations for our product pipeline, in- line products and product candidates,
including anticipated regulatory submissions, data read- outs, study starts, approvals, revenue contribution, growth, performance,
timing of exclusivity and potential benefits, and our efforts to respond to COVID -19, including our development of a vaccine to
help prevent COVID -19, that are each subject to substantial risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. Among other things, statements regarding revenue and earnings
per share growth; the development or commercial potential of our product pipeline, in- line products, product candidates and
additional indications, including expected clinical trial protocols, the timing of the initiation and progress of clinical tr ials and data
read- outs from trials; the timing for the submission of applications for and receipt of regulatory approvals; expected
breakthrough, best or first -in-class status, blockbuster status of our medicines; and the impact of anticipated improvements to
our clinical operation performance are forward- looking and are estimates that are subject to change and clinical trial and
regulatory success. These statements are subject to risks, uncertainties and other factors that may cause actual results to diff er
materially from past results, future plans and projected future results. Additional information regarding these and other factor s
can be found in Pfizer’s Annual Report on Form 10- K for the fiscal year ended December 31, 2020 and in our subsequent
reports on Form 10- Q, including in the sections thereof captioned “Risk Factors” and “Forward- Looking Information and Factors
That May Affect Future Results”, as well as in our subsequent reports on Form 8- K, all of which are filed with the U.S. Securities
and Exchange Commission and available at www.sec.gov and www.pfizer.com. Potential risks and uncertainties also include the impact of COVID -19 on our sales and operations, including impacts on employees, manufacturing, supply chain, marketing,
research and development and clinical trials.
•The forward- looking statements in these presentations speak only as of the original date of the presentation and we undertake
no obligation to update or revise any of these statements. Today’s discussions and presentations are intended for the investor community only; they are not intended to promote the products referenced herein or otherwise influence healthcare prescribingdecisions. All trademarks in today’s presentations are the property of their respective owners.Forward -Looking Statements and Other Notices 3 Oncology
Pfizer Oncology Leadership
Global PresidentChris Boshoff
Preview truncated — download the full document for the complete content.
investor_presentation
129 Pages
investor_presentation
20 Pages
Kilroy Realty